Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VeRiTAs study of first-line venetoclax plus rituximab in young fit patients with high-risk chronic lymphocytic leukemia
2018-000877-61Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by GIMEMA. Primary endpoint: Complete response rate at end of treatment. Started Jun 2021; status: completed.
02
Drugs
venetoclaxrituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2018-000877-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000877-61.